Clinical Trial Update: Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating atezolizumab plus varlilumab with or without cobimetinib in advanced biliary tract cancers, with results posted in May 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer
• Distal Bile Duct Cancer
• Gallbladder Cancer
• Intrahepatic Cholangiocarcinoma

Drugs mentioned

• Atezolizumab (atezolizumab)
• CDX-1127 (Varlilumab) (varlilumab)
• Cobimetinib (cobimetinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Distal Bile Duct Adenocarcinoma, Metastatic Gallbladder Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-05-23